Financials data is unavailable for this security.
View more
Year on year Arovella Therapeutics Ltd had revenues fall -64.27% from 435.92k to 155.74k, though the company grew net income from a loss of 10.18m to a smaller loss of 8.75m.
| Gross margin | 100.00% |
|---|---|
| Net profit margin | -5,616.16% |
| Operating margin | -5,610.62% |
| Return on assets | -93.26% |
|---|---|
| Return on equity | -116.55% |
| Return on investment | -116.36% |
More ▼
Cash flow in AUDView more
In 2024, Arovella Therapeutics Ltd increased its cash reserves by 145.67%, or 7.54m. Cash Flow from Financing totalled 14.61m or 9,380.59% of revenues. In addition the company used 6.91m for operations while cash used for investing totalled 179.34k.
| Cash flow per share | -0.0092 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.0107 |
|---|---|
| Tangible book value per share | 0.0107 |
More ▼
Balance sheet in AUDView more
| Current ratio | 6.45 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
